Slovak biotechnological specialists Axon Neuroscience developed a vaccine from Alzheimer’s disease, capable of slowing down the deterioration of cognitive functions. More about her, they told in the article in the magazine Nature Aging.
193 patients with a light form of Alzheimer’s disease participated in the study. 117 During 24 months, 11 doses of Vaccine AADVAC1, the remaining placebo received. The vaccine was able to slow down the accumulation of fine peptide neurofilament, protein associated with a faster deterioration of cognitive functions.
A significant difference in tests on cognitive functions in two groups in general, researchers did not reveal. However, comparing a group receiving a placebo, and a subgroup with the highest values of biomarkers, testifying to the presence in the brain of clusters of Tau-protein and beta-amyloid, scientists concluded that the vaccine is capable of slowing down the deterioration of cognitive functions by almost a third.
The study was conducted on a small sample and was directed primarily to understand whether the vaccine is safe, the authors of the work are noted. In this regard, the drug justified itself without causing any clinically significant side effects. However, to explore its effectiveness, tests are needed on more person. They are scheduled for early 2022.